This study is being offered to patients who have castrate-resistant (also known as
hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the
prostate area to other parts of the body.
The purpose of this study is to evaluate the effects of sequencing hormonal therapies
(abiraterone acetate and enzalutamide) and to assess treatment efficacy of these two agents.